Let's Drive
the Future
of HS

The INTREPID HS Study is a year-long clinical research study designed to evaluate the safety and efficacy of an investigational drug compared to a placebo (something that looks like the investigational drug but has no effect on the body) in reducing symptoms and improving the quality of life for participants living with HS. 

If you qualify, you will have a random chance of receiving the investigational drug or placebo for 16 weeks, both administered as weekly subcutaneous (under the skin) injections. After this, all participants, including those initially assigned to receive the placebo, will receive the investigational drug either weekly or every other week. Overall, the study includes approximately 18 study visits. Those who successfully complete the study may be eligible to enroll in a separate long-term extension study to continue receiving the investigational drug.